KINTOR PHARMACEUTICAL LIMITED Financials Kintor Pharmaceutical Limited
Equities
9939
KYG5273B1077
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.12 HKD | +0.90% |
|
+5.66% | -31.29% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,252 | 3,884 | 3,893 | 463.5 | 463.5 | - |
| Enterprise Value (EV) 1 | 2,085 | 2,989 | 3,304 | 663 | 463.5 | 463.5 |
| P/E ratio | - | -4.25 x | -3.44 x | -0.6 x | -0.58 x | -0.75 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | 113 x | - | - | 4.5 x | 1.19 x |
| EV / Revenue | - | 87.3 x | - | - | 4.5 x | 1.19 x |
| EV / EBITDA | -4.18 x | -3.61 x | -3.57 x | -0.64 x | -0.62 x | -0.88 x |
| EV / FCF | -4.6 x | -2.51 x | -3.34 x | -0.8 x | -0.56 x | -0.78 x |
| FCF Yield | -21.7% | -39.9% | -29.9% | -125% | -178% | -129% |
| Price to Book | 1.81 x | 2.16 x | 2.19 x | - | - | - |
| Nbr of stocks (in thousands) | 369,390 | 387,590 | 447,500 | 447,500 | 447,500 | - |
| Reference price 2 | 8.804 | 10.02 | 8.699 | 1.036 | 1.036 | 1.036 |
| Announcement Date | 26/03/21 | 25/03/22 | 30/03/23 | 28/03/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | 34.23 | - | - | 103 | 388 |
| EBITDA 1 | -498.2 | -828.9 | -926.1 | -1,040 | -746 | -529 |
| EBIT 1 | -504.9 | -839.6 | -944.5 | -1,059 | -741 | -525 |
| Operating Margin | - | -2,452.75% | - | - | -719.42% | -135.31% |
| Earnings before Tax (EBT) 1 | -508.2 | -842.1 | -953.3 | -1,069 | -800 | -615 |
| Net income 1 | -508.3 | -842.1 | -954.4 | -1,061 | -800 | -615 |
| Net margin | - | -2,460.04% | - | - | -776.7% | -158.51% |
| EPS 2 | - | -2.360 | -2.530 | -2.470 | -1.790 | -1.380 |
| Free Cash Flow 1 | -452.8 | -1,192 | -988.7 | -1,319 | -824 | -597 |
| FCF margin | - | -3,483.15% | - | - | -800% | -153.87% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 26/03/21 | 25/03/22 | 30/03/23 | 28/03/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 589 | - | - |
| Net Cash position 1 | 1,167 | 895 | 589 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | -0.6611 x | - | - |
| Free Cash Flow 1 | -453 | -1,192 | -989 | -1,319 | -824 | -597 |
| ROE (net income / shareholders' equity) | -54.1% | -50.9% | -54.5% | -56.3% | -53.5% | -41.1% |
| ROA (Net income/ Total Assets) | -42.3% | -41.1% | - | -51.4% | -48.5% | -36.5% |
| Assets 1 | 1,202 | 2,051 | - | 1,636 | 1,649 | 1,685 |
| Book Value Per Share | 4.870 | 4.640 | 3.970 | - | - | - |
| Cash Flow per Share | -1.230 | -2.950 | - | - | - | - |
| Capex 1 | 69 | 76.2 | 27.5 | 222 | 91 | 91 |
| Capex / Sales | - | 222.61% | - | - | 88.35% | 23.45% |
| Announcement Date | 26/03/21 | 25/03/22 | 30/03/23 | 28/03/24 | - | - |
1CNY in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.036
CNY
Average target price
13.21
CNY
Spread / Average Target
+1,175.51%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -31.29% | 64.14M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- 9939 Stock
- Financials Kintor Pharmaceutical Limited
